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Abstract
Background: For optimal T cell activation it is desirable that dendritic cells (DCs) display peptides
within MHC molecules as signal 1, costimulatory molecules as signal 2 and, in addition, produce IL-
12p70 as signal 3. IL-12p70 polarizes T cell responses towards CD4+ T helper 1 cells, which then
support the development of CD8+ cytotoxic T lymphocytes. We therefore developed new
maturation cocktails allowing DCs to produce biologically active IL-12p70 for large-scale cancer
vaccine development.
Methods: After elutriation of leukapheresis products in a closed bag system, enriched monocytes
were cultured with GM-CSF and IL-4 for six days to generate immature DCs that were then
matured with cocktails, containing cytokines, interferon-gamma, prostaglandin E2, and a ligand for
Toll-like receptor 8, with or without poly (I:C).
Results: Mature DCs expressed appropriate maturation markers and the lymph node homing
chemokine receptor, CCR7. They retained full maturity after culture for two days without
maturation cocktails and following cryopreservation. TLR ligand stimulation induced DCs capable
of secreting IL-12p70 in primary cultures and after one day of coculture with CD40L-expressing
fibroblasts, mimicking an encounter with T cells. DCs matured with our new cocktails containing
TLR8 ligand, with or without poly (I:C), induced alloresponses and stimulated virus-specific T cells
after peptide-pulsing. DCs matured in cocktails containing TLR8 ligand without poly (I:C) could also
be loaded with RNA as a source of antigen, whereas DCs matured in cocktails containing poly (I:C)
were unable to express proteins following RNA transfer by electroporation.
Conclusion: Our new maturation cocktails allowed easy DC harvesting, stable maturation and
substantial recoveries of mature DCs after cryopreservation. Our procedure for generating DCs
is easily adaptable for GMP-compliance and yields IL-12p70-secreting DCs suitable for development
of cancer vaccines using peptides or RNA as sources of immunizing antigens.
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Background
Dendritic cells (DCs) are superior antigen presenting cells
that regulate the quality and the magnitude of immune
responses [1]. DCs develop from bone marrow-derived
progenitors and display an enormous plasticity with
respect to lineage ontogeny, body location and functional
diversity, with resultant differences in stimulatory capac-
ity [2]. Recent discoveries describe mutual interference [3]
and even distinct divisions of labor by different DC sub-
types [4].
In vivo, immature- or intermediate-stage DCs patrol
peripheral tissues to capture and process antigens [5].
Under the influence of local cytokines and danger signals,
DCs undergo complex maturation processes and migrate
to regional lymph nodes, where they form immunological
synapses with T cells and present peptides derived from
collected antigens in context with MHC class I or II mole-
cules. They also provide costimulation and instructive sig-
nals (such as cytokines) that mirror the micromilieu
under which they matured [6]. DCs can polarize immune
responses, depending on the cytokines they secrete, yield-
ing effector cells with different functional capacities.
Thereby, DCs utilize unique features to induce responses
in naïve T cells and ensure adequate effector functions [7].
Accordingly, DCs can serve as "natural adjuvants" in ther-
apeutic vaccines for diseases with immunological dys-
function, including malignant disorders [8], infections
and even allergic and autoimmune reactions [9].
Since DCs occur in only small numbers in blood, it is
arduous to isolate them via antibody tagging for ex vivo
manipulation [10]. In vivo targeting of DCs, as described
recently via DC-specific molecules like DEC-205 [11] or
DC-SIGN [12], would be highly advantageous but at
present is complicated. Therefore, most current clinical
applications depend on differentiation of bone marrow or
peripheral blood DC progenitors using recombinant
cytokines [13]. Numerous protocols exist to generate
human DCs in vitro from CD34-positive cells or mono-
cytic progenitors. Immature DCs (iDCs) are relatively easy
to obtain in sufficient numbers from monocytes follow-
ing culture with GM-CSF and IL-4. DC maturation can
then be induced using inflammatory signals, such as
tumor necrosis factor (TNF), interleukin-1 beta (IL-1β), or
bacterial derivatives (e.g. lipopolysaccharide, lipotei-
chonic acid, or Ribomunyl), double-stranded RNA, inter-
ferons and/or prostaglandins [14].
There is substantial discussion whether DCs can function
as tumor vaccines, based on the outcome of numerous
clinical studies of different malignancies showing only
limited rates of objective tumor regression in patients
with advanced disease [15,16]. To date, most DC vaccina-
tion studies have utilized either iDCs or mature DCs
(mDCs) not having a capacity to secrete biologically
active IL-12. Thus, the question remains whether usage of
DCs secreting this important cytokine would help to gen-
erate more effective cancer vaccines.
DCs producing IL-12p70 are desired for cancer vaccine
development because of their leading role in promoting T
helper 1 (Th1) cell polarization [17]. CD4+ Th1 cells, in
turn, support development of CD8+  cytotoxic T lym-
phocytes, fostering the appropriate adaptive immune
responses needed to combat minimal residual disease and
control the outgrowth of malignant cells in tumor
patients. IL-12p70-producing DCs can also support
innate immunity through induction of natural killer (NK)
cell proliferation. It has been shown that ligation of par-
ticular Toll-like receptors (TLRs) is a prerequisite to
induce full maturation, enabling DCs to produce IL-
12p70 [18].
Currently, a cocktail described by Jonuleit and coworkers
is used commonly in clinical studies for DC maturation
[19]. However, DCs matured with Jonuleit cocktail fail to
produce IL-12p70. In contrast, Kalinski and coworkers
described an alternative cocktail that provides mature DCs
producing IL-12p70 [20]. In preliminary experiments, we
experienced harvesting and handling problems of mDCs
using this alternative cocktail. Therefore, we sought to
establish new cocktails that would allow large-scale
processing of clinical-grade mDCs with the capacity to
secrete IL-12p70. To this end, we selected components of
the Jonuleit cocktail that had a positive impact on DC
maturation (TNF and IL-1β) while eliminating IL-6 which
can inhibit IL-12p70 secretion. PGE2 was added at a low
concentration to improve DC handling by reducing cell
adherence. Finally, interferon-gamma (IFNγ) and the
TLR8 ligand, R848 (Resiquimod), were included to
induce IL-12p70 synthesis. Further amplification was
achieved using poly (I:C) in one cocktail formulation.
Since our vaccine strategies primarily envision using RNA
as a source of tumor-associated antigens [21], it was also
essential to establish that good protein expression would
be obtained following RNA transfer into DCs generated in
large-scale and matured with the new cocktails.
Methods
Leukapheresis and elutriation
To obtain monocytes as progenitor cells for generation of
DCs, we used a closed bag system of elutriation using the
ELUTRA instrument (Gambro BCT, Lakewood, CO, USA).
After informed consent, healthy, untreated donors under-
went 180 min leukapheresis (COBE Spectra; Gambro
BCT) using a modified PBSC program: the separation fac-
tor was set to 700 with a collection rate of 0.8 mlmin and
a target hematocrit of 1–2%. Harvested cells were ana-
lysed by an automatic blood counter (ACT Dif, BeckmanJournal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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Coulter, Krefeld, Germany) to set up parameters for the
ELUTRA system.
Leukapheresis products were processed by ELUTRA,
according to the manufacturer's instructions, by a method
of counter-flow centrifugal elutriation using a fixed rotor
speed (2400 rpm) and computer-controlled stepwise
adjustment of medium flow rate, with rotor-off harvest-
ing. Five liters of HANKs buffered salt solution (Bio-
chrom, Berlin, Germany) with 1% human serum albumin
(Octalbine®, Octapharma, Langen, Germany) were uti-
lized for cell separation. ELUTRA processing yielded five
fractions; enriched monocytes were present in fraction 5
and enriched lymphocytes were present in fraction 3. All
fractions were characterized by automatic blood counter
(ACT Dif) and flow cytometry.
Generation of immature DCs from elutriated monocytes
Cells from fraction 5 were used directly for DC generation
when CD14-positive monocytes represented more than
60% of cells detected by FACS. Fraction 5 cells were har-
vested from the collecting bag, washed once with PBS +
0.5% human serum and seeded at 35 × 106/175 cm2 cell
culture flask (Nunc, Wiesbaden, Germany) in 35 ml DC
medium containing RPMI 1640 with very low endotoxin
(Biochrom), 1.5% human serum (pool of AB-positive
adult males) (DRK-Blood Bank, Suhl, Germany) and 10
μg/ml gentamycin (Biochrom). They were cultivated for 6
days at 37°C, with 5% CO2 in a humidified atmosphere
and on days 1, 3 and 6, cultures were supplemented with
100 ng/ml GM-CSF (Leukine® by Berlex, Richmond, USA)
and 20 ng/ml recombinant human IL-4 (R&D Systems,
Wiesbaden, Germany) in 7 ml fresh DC medium.
Maturation of DCs
Maturation was induced by adding different cocktails to
iDCs on day 6, along with 7 ml fresh DC medium. Five
cocktails were compared, including the Jonuleit [19] and
Kalinski [20] cocktails that were described previously. The
following components were utilized: TNF, IL-1β, IL-6
(R&D Systems); prostaglandin E2 (PGE2) (Minprostin®,
Pharmacia/Pfizer, Erlangen, Germany); IFNα (Roferon A®,
Roche, Welwyn Garden City, England); IFNγ (Imukin®,
Boehringer Ingelheim, Ingelheim, Germany); double-
stranded RNA (poly (I:C) and R848 (InVivogen, Tou-
louse, France). The exact composition of individual cock-
tails is provided in "Results". One flask of cells received
only 7 ml fresh medium which served as the iDC control
(data not shown). After incubation in maturation cock-
tails for 24 h, DCs were harvested by washing culture
flasks twice in PBS + 0.5% human serum, with light shak-
ing.
Wash-out test
To analyze the stability of maturation, DCs were washed
as described above and reseeded at 2.5–3 × 106/9 ml fresh
DC medium without any cytokines in 25 cm2 culture
flasks (Nunc). After approximately 44 h, DCs were har-
vested and phenotyped using selected antibodies.
Cryopreservation of DCs
After harvesting and washing, 20–25 × 106 DCs were col-
lected in 0.5 ml cold 20% human serum albumin (Octal-
bine®, Octapharma, Langen, Germany), gently mixed with
freezing solution containing 10% glucose (Braun, Mel-
sungen, Germany), 20% DMSO (CryoSURE®, WAK-
Chemie, Dessau-Thornau, Germany) in 20% human
serum albumin [22]. Cryotubes (Nunc), were stored over-
night at -80°C in a special freezing container (Nalgene
Nunc Intl. Corp. Rochester, N.Y., USA) and transferred
into the gas phase of a liquid nitrogen container.
FACS analysis of DCs
DCs were labeled with the following fluorescence-conju-
gated mouse monoclonal antibodies with appropriate
isotype controls (clone X-40), CD14 (FITC, MΦP9),
CD19 (FITC, clone: 4G7), CD86 (FITC, clone: 2331 FUN-
1), CD80 (PE, clone: L307.4) (BD Biosciences); CD209
(PE, clone: DCN46) (Pharmingen, San Diego, USA); CD3
(FITC, clone: UCHT1, CD56 (FITC, clone: C5.9a), CD1a
(FITC, clone: NA1/34) (Dako); HLA-DR (PE, clone:
B8.12.2), CD40 (PE, clone: mAb89) and CD83 (PE,
clone: HB15a) (Immunotech). CCR7 was detected using
rat BLR-2 hybridoma supernatant medium (clone 8E8; E.
Kremmer, GSF) with an IgG2a isotype control superna-
tant medium (EBNA-A2; clone R3, E. Kremmer) by incu-
bation for 60 min, followed by washing and detection
with a secondary mouse antibody against rat IgG conju-
gated with cyanin 5 (Jackson Immuno, West Grove, USA).
Mature DCs electroporated with EGFP (enhanced green
fluorescent protein)-encoding RNA were recultured with
cocktails for 24 or 48 h, harvested, washed and green flu-
orescence was analyzed by flow cytometry within 1 h. To
test vitality, DCs were pelleted and resuspended for 20
min in 7-amino-actinomycin D (Sigma-Aldrich, Deisen-
hofen, Germany) at a final concentration of 10 μg/ml in
PBS + 2% fetal calf serum. After washing, 7AAD incorpo-
ration by dead cells were measured in the third channel of
the FACS-Calibur flow cytometer.
Signal-3 assay
DCs were cocultured with stimulating cells that mimicked
T cells, as described previously [20,23]. Briefly, mDCs
were reseeded in 96-well plates at 2 × 104cells/well and
incubated with 5 × 104 cells/well of mouse fibroblast L-
cells stably transfected to express human CD40-Ligand
(CD40L) [24]. As controls, DCs and L-cells were cultured
alone in medium without cytokines. After 24 h, platesJournal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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were centrifuged and supernatants of eight replicate wells
were pooled for analysis of IL-12p70 and IL-10 by ELISA.
ELISA (IL-12p70/IL-10)
IL-12p70 and IL-10 secreted by DCs during the matura-
tion process (primary DCs) and in the signal-3 assay were
detected by standard ELISA, utilizing antibody duo-sets
(R&D Systems), according to the manufacturer's instruc-
tions. Colorimetric substrate reactions using tetramethyl-
benzidine and H2O2 were stopped with H3PO4, measured
at 450 nm with wavelength correction at 620 nm, and
analyzed by "easy fit" software (SLT, Crailsheim, Ger-
many).
Mixed lymphocyte reaction
Mature DCs were washed twice in PBS + 0.5% human
serum, irradiated with 40 Gy and 1 × 104cells/well plated
in 96-well round bottom microplates (Nunc) in RPMI
1640 + 1.5% human serum. Cryopreserved cells from
ELUTRA fraction 3 (lymphocyte-enriched fraction) were
used as responder cells at a concentration of 1 × 105 cells/
well. As controls for T cell activation, third party mononu-
clear cells (MNCs) from buffy coats of five unrelated
donors were pooled and used as stimulating cells after
irradiation with 40 Gy. T cell proliferation was also con-
trolled by addition of IL-2 (Proleukin®, Chiron, Emery-
ville, CA, USA) at 50 IU/ml, or 5 IU/ml in combination
with phytohaemagglutinin (PHA) at 10 μg/ml (Sigma-
Aldrich, Deisenhofen, Germany). After 6 days, cells were
pulsed with 0.5 μCi/well 3H-thymidine (Amersham-Phar-
macia, Freiburg, Germany) and radioactivity measured
after 24 h.
ELISPOT assay of virus-specific T cell activation
For activation, lymphocytes from ELUTRA fraction 3 were
plated at 1 × 106 cells/well with 1 × 105 viral peptide-
loaded DCs in 24-well plates, in RPMI 1640 medium with
10% human serum; 30 IU/ml IL-2 was added at d3 and
lymphocytes harvested at d7. HLA-A*0201-binding pep-
tides included: CMVpp65495–503  (NLVPMVATV), EBV-
BMLF1280–288 (GLCTLVAML), influenza M1 protein58–66
(GILGFVFTL) or the CEF pool (PANATecs GmbH, Tuebin-
gen, Germany) containing two additional peptides, EBV-
LMP-2426–434(CLGGLLTMV) and influenza RNA polymer-
ase PA46–54 (FMYSDFHFI). In vitro activated T cells and
autologous monocytes plus CEF peptides were incubated
in RPMI 1640 medium containing 2 mM L-glutamine, 1
mM sodium pyruvate, penicillin/streptomycin (100 U/
ml), 10% human AB serum (BioWhittaker, Verviers, Bel-
gium) and 20 IU/ml IL-2 at 37°C with 5% CO2 for 24 h.
IFNγ-ELISPOT analysis was performed as described
[25,26], with the exception that antibody precoated PVDF
plates (Mabtech AB, Nacka, Sweden) and streptavidin-
alkaline phosphatase and a ready-to-use BCIP/NBT-plus
substrate solution (Mabtech) were used for detection.
Spots were counted using the AID reader system ELR03
with 3.2.3 software (AID Autoimmun Diagnostika
GmbH, Strassberg, Germany).
EGFP-RNA transfection into DCs
EGFP-RNA was produced in vitro and electroporated into
mDCs at 24 h, as described previously [27,28] with the
exception that each 0.4 cm electroporation cuvette con-
tained a total volume of 300 μl, including 8 μg of EGFP-
RNA and 3× 106 DCs. After electroporation, mDCs were
returned to their original maturation media and incu-
bated in a 24-well plate at 37°C and 5% CO2 for 24 or 48
h before flow cytometric analysis.
Results
Establishment of primary DC cultures using elutriated 
monocytes
Monocytic progenitor cells were obtained by elutriation
of leukapheresis products of healthy donors. In order to
assess a variety of parameters, DCs obtained from mono-
cytes of one donor were used throughout an extensive
series of experiments examining phenotype and function;
one full set of these experiments is shown here. (Fig. 1).
The stepwise procedures and characterization of primary
DCs generated from this donor are representative of
results obtained with different donors in independent
experiments. ELUTRA fraction 5 from this donor con-
tained 80.6% CD14-positive cells and the following con-
taminants: 2.9% CD3-, 2.2% CD56-, 1.5% CD19- and
7.7% CD67-positive cells (data not shown) and therefore
was of appropriate quality to prepare DCs. Following gen-
eration of iDCs using GM-CSF and IL-4, cells were
matured by incubation with the various maturation cock-
tails listed in Table 1. Recoveries of mDCs, based on total
numbers of seeded cells and starting numbers of CD14-
positive monocytes, were lower in DC2 (Kalinski) cocktail
compared to DC1 (Jonuleit) cocktail (Fig. 2A), due to cell
loss through strong plastic adherence of DC2 cells. DC
viability ranged from 88.8% to 97.9%, with the lowest
value for DC2 cells. The monocyte marker CD14 disap-
peared and the mDC marker CD83 appeared, thereby
demonstrating that all populations contained highly
mature DCs (Fig. 2A, 2B). High expression of costimula-
tory molecules, like CD80 and CD86, reflected the typical
phenotype of mDCs, and chemokine receptor CCR7
(CD197) expression indicated that the majority of DCs
had migratory potential for lymph nodes (Fig. 2A, 2B).
Table 2 summarizes the phenotypic analyses of primary
DCs prepared in independent experiments from different
donors matured in the various cocktails, demonstrating
that there were no substantial differences with respect to
surface marker expression among the mDCs.
To determine if maturation was stable, the same mDCs
were evaluated after 44 h of re-culture in medium withoutJournal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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Time-line of experimental setup using monocytes derived from one representative donor Figure 1
Time-line of experimental setup using monocytes derived from one representative donor. Monocytes were pre-
pared from a leukapheresis by elutriation on day 0 and cultured for 6 days with GM-CSF and IL-4 to produce iDCs, which were 
then incubated with different maturation cocktails. After 24 h, mDCs were harvested and washed twice, phenotypes deter-
mined by FACS and aliquots were cryopreserved. The primary culture supernatants were collected to assess IL-12p70 and IL-
10 by ELISA. Samples of the different DC populations were cocultured with fibroblast L-cells (signal-3 assay) for an additional 
24 h and supernatants collected once again for IL-12p70 and IL-10 measurements. Mixed lymphocyte cultures were established 
using autologous and allogeneic lymphocytes (fraction 3 of elutriated leukaphesis cells, cryopreserved on day 0) as responding 
cells and DC1–DC5 cells as stimulating cells. Tritiated-thymidine incorporation into dividing cells was measured during the final 
24 h of a 7-day coculture. Mature DC1–DC5 cells that were harvested and washed on day 7 were loaded with CEF peptides 
and used as stimulating cells for autologous lymphocytes (fraction 3 cells after elutriation, cryopreserved on day 0). Lym-
phocytes and the various DC populations were cocultured for 7 days, washed and restimulated with autologous monocytes 
(fraction 5 cells, cryopreserved on day 0), with or without CEF peptides. IFNγ secretion was assessed in a standard ELISPOT 
analysis 24 h later. DCs cryopreserved on day 7 were thawed and reassessed for phenotype after storage in liquid nitrogen. 
Cryopreserved monocytes (fraction 5 from day 0) were thawed and used to generate new mDCs which were loaded with 
EGFP RNA by electroporation on day 7. Flow cytometry to detect percentages of positive cells and intensity of fluorescence 
was performed at 24 h.Journal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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Table 1: Cocktail compositions used for DC maturation
DC population Cocktaila Inflammatory cytokines/interferons Other 
additives
TRL-ligands Comments
DC1 Jonuleit TNF, IL-1β, IL-6 PGE2 - no TLR ligands
DC2 Kalinski TNF, IL-1β, IFNα, IFNγ - poly (I:C) TLR3/non-TLR ligand
DC3 Cocktail 3b TNF, IL-1β, IFNγ PGE2 R848 TLR8 ligand, less IFNγ and PGE2
DC4 Cocktail 4b TNF, IL-1β, IFNγ PGE2 R848 TLR8 ligand
DC5 Cocktail 5b TNF, IL-1β, IFNγ PGE2 R848, poly (I:C) TLR3/non-TLR, TLR8 ligands
a The following concentrations were used for the individual cocktails: Jonuleit: 10 ng/ml TNF, 10 ng/ml IL-1β, 15 ng/ml IL-6 and 1 μg/ml prostaglandin 
E2; Kalinski: 10 ng/ml TNF, 10 ng/ml IL-1β, 3000 IU/ml IFNα, 1000 IU/ml IFNγ and 20 ng/ml poly (I:C); Cocktail 3: 10 ng/ml TNF, 10 ng/ml IL-1β, 
1000 IU/ml IFNγ, 1 μg/ml R848 and 100 ng/ml prostaglandin E2; Cocktail 4: 10 ng/ml TNF, 10 ng/ml IL-1β, 5000 IU/ml IFNγ, 1 μg/ml R848 and 250 
ng/ml prostaglandin E2; Cocktail 5: 10 ng/ml TNF, 10 ng/ml IL-1β, 5000 IU/ml IFNγ, 1 μg/ml R848, 250 ng/ml prostaglandin E2 and 20 ng/ml poly 
(I:C).
b These represent compositions first reported here.
Table 2: Characteristics of primary DCs following maturation with different cocktails
Parameter DC1 DC2 DC3 DC4 DC5
R e c o v e r y  ( %  s e e d e d  c e l l s ) N * 44322
m+ 32.8 17.6 19.0 17.9 18.1
std# 18.7 9.2 5.5 3.0 6.0
Recovery (% CD14+c e l l s ) N * 44332
m+ 42.6 22.2 25.4 24.0 25.5
std# 22.0 9.7 6.2 2.8 3.1
%  v i a b l e  c e l l s  ( 7 A A D - n e g  c e l l s ) N * 55453
m+ 97.5 88.9 96.0 96.0 94.0
std# 0.9 3.7 1.6 1.2 1.4
% CD14+c e l l s N * 55453
m+ 2.2 2.5 1.6 2.5 3.1
std# 2.2 3.0 0.9 3.1 4.1
% CD83+ c e l l s N * 55453
m+ 94.2 82.3 95.1 90.6 92.4
std# 3.0 7.1 2.3 10.7 1.7
% CCR7+ c e l l s N * 55453
m+ 79.7 67.5 75.2 74.4 85.2
std# 7.2 5.6 8.7 11.8 0.7
% CD80+ c e l l s N * 55453
m+ 80.7 70.8 83.2 85.5 85.3
std# 12.5 10.9 10.7 8.9 11.0
% CD86+ c e l l s N * 55453
m+ 95.1 89.6 94.2 94.7 95.8
std# 2.2 4.5 2.2 2.1 0.8
* N = number of independent donors
+ m = mean
#std = standard deviationJournal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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Generation of stable, mature DCs using different maturation cocktails Figure 2
Generation of stable, mature DCs using different maturation cocktails. (A) Percentages of DCs harvested after pri-
mary cell culture (6 d differentiation + 24 h maturation) calculated on total seeded cells (mononuclear cells) or CD14-positive 
monocytes detected by FACS and manual counting. DC populations DC1–DC5 were matured in different cocktails as listed in 
Table 1. Viability was detected by 7AAD exclusion measured by flow cytometry in FL-3 of the FACS-Calibur and viable cells 
are expressed as percentages of total cells. Percentages of cells expressing various surface markers were determined by flow 
cytometry using the antibodies specified in "Methods", including CD14 (a monocyte marker), CD83 (a marker of mDCs), 
CD80 and CD86 (costimulatory molecules) and chemokine receptor 7 (CCR7 = CD197) as an indicator for DC migratory 
potential into lymph nodes. Data are expressed as percentages of total cells with acquisition of 1 × 104 events. CCR7 values 
presented here (Fig. 2A) represent the percentages in histograms overlayed by IgG2a isotype control, although generated from 
the same FACS stain they are slightly different to the CCR7 values shown as dot plots in Figure 2B. Broken lines indicate 
marker levels for DCs matured with DC1 (Jonuleit) cocktail. (B) Representative dot plots of DC1–DC5 populations showing 
percentages of cells positive for CD83 versus CCR7 and CD80 versus CD86. (C) DCs were washed free of maturation 
cytokines and cultured an additional 44 h in culture medium without cytokines. Viability was determined by 7AAD incorpora-
tion. Percentages of CD14, CD83, CD80, CD86 and CCR7 were determined as described above. Broken lines indicate marker 
levels for DCs matured with DC1 (Jonuleit) cocktail.Journal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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cytokines (Fig. 2C). As expected, some viability was lost,
nevertheless more than 80% viable cells were recovered in
all cases. No reversal of differentiation was observed since
all DCs remained CD14-negative and retained high levels
of CD83, CD80, CD86 and CCR7. Thus, all cocktails
induced stable maturation of DCs. The stability of matu-
ration, as assessed for DCs prepared from different donors
in independent experiments is summarized in Table 3,
revealing that DC3, DC4 and DC5 cells were comparable
to cells matured in DC1 (Jonuleit) and DC2 (Kalinski)
cocktails.
Recovery of DCs after cryopreservation
Cryopreserved mDCs were stored in the gas phase of liq-
uid nitrogen and subsequently thawed for assessment of
viability and phenotype. Viabilities of over 80% were
found with mature DC1, DC3 and DC4 populations. In
contrast, the viabilities of DC2 and DC5 cells, both
Table 3: Characteristics of DCs from different donors following wash-out of maturation cocktails and cryopreservation
Parameter DC1 DC2 DC3 DC4 DC5
Wash-out
%  v i a b l e  c e l l s N * 55452
m+ 93.4 81.4 84.9 87.4 80.2
std# 4.2 4.2 5.0 3.6 4.8
% CD14+ c e l l s N * 55442
m+ 0.9 4.7 0.8 2.3 3.6
std# 1.0 7.3 0.4 3.3 4.7
% CD83+ c e l l s N * 55452
m+ 91.7 79.3 86.5 86.1 88.2
std# 3.0 8.4 6.8 6.5 8.2
% CCR7+c e l l s N * 55452
m+ 89.4 71.4 81.7 86.1 76.1
std# 4.3 15.1 6.6 4.6 6.9
Cryopreservation
%  v i a b l e  c e l l s N * 32232
m+ 86.5 60.6 81.8 84.5 64.2
std# 4.0 4.4 2.1 1.8 14.9
% CD14+ c e l l s N * 32232
m+ 1.6 0.4 0.5 1.9 1.8
std# 2.2 0.3 0.2 2.5 2.1
% CD83+c e l l s N * 33232
m+ 95.8 84.9 97.5 96.1 95.3
std# 2.1 7.3 0.0 1.1 3.9
% CCR7+ c e l l s N * 32232
m+ 81.3 76.3 80.7 81.6 84.5
std# 6.6 7.4 2.5 6.3 0.2
% CD80+c e l l s N * 32232
m+ 80.6 71.6 87.8 90.4 82.7
std# 5.6 3.8 4.4 0.9 3.7
% CD86+ c e l l s N * 32232
m+ 96.3 94.8 96.9 96.0 93.5
std# 2.7 0.8 0.9 1.4 6.8
* N = number of independent donors
+ m = mean
#std = standard deviationJournal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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matured in cocktails containing poly (I: C), dropped to
63% and 74%, respectively. High expression of CD83,
CD80, CD86 and CCR7 was retained on all DCs and very
few CD14-positive cells were detected (data not shown).
Therefore, mDCs could be recovered after cryopreserva-
tion with a maturation status suitable for clinical use, as
shown in comparisons of DCs prepared from additional
donors in independent experiments (Table 3).
IL-12p70 and IL-10 release by mDCs
Our primary goal was to create cocktails that yielded
mDCs with a capacity to produce IL-12p70 that could be
easily produced in large-scale. Figure 3A shows secretion
of biologically active IL-12p70 and IL-10 by primary
mDCs into culture supernatant media. DC1 cells did not
produce any IL-12p70, whereas DC2–DC5 cells secreted
IL-12p70 in the ng/ml ranges. As a second assay, mDCs
were coincubated with fibroblast L-cells transfected to
Production of IL-12p70 and IL-10 by DCs matured using different cocktails Figure 3
Production of IL-12p70 and IL-10 by DCs matured using different cocktails. Immature DCs were cultured with dif-
ferent maturation cocktails and the amounts of IL-12p70 and IL-10 were determined by standard ELISA. Filled bars indicate IL-
12p70 and empty bars IL-10, respectively. Cytokine content was measured (A) in supernatant medium of primary maturation 
cultures after 7 d and (B) in supernatant medium of cultures containing washed mDCs and CD40L-transfected fibroblasts fol-
lowing coculture for 24 h, representing a signal-3 assay as described in "Methods". (C) The quotients of IL-12p70/IL-10 were 
determined for the DC populations matured in different cocktails, based on the pg/ml values of the signal-3 assay. For calcula-
tion of quotients, it was assumed that IL-12p70 and IL-10 have theoretically equal biological potential. Filled circles indicate 
quotients ranging from 0 (DC1 cells in Jonuleit cocktail) to 3.2 (DC5 cells in cocktail 5). The values of DCs matured in DC1 
(Jonuleit) versus DC2 (Kalinski) cocktails are indicated by broken lines.Journal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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express human CD40L, thereby mimicking an encounter
of DCs with T cells (Fig. 3B). CD40L-stimulation induced
renewed IL-12p70 secretion from DC2 and DC5 cells and
to a lesser extent from DC3 and DC4 cells, whereas no IL-
12p70 was found with DC1 cells. Because IL-10 counter-
acts IL-12, we calculated the quotient of IL-12p70/IL-10
for all mDCs (Fig. 3C). DC1 cells had the lowest quotient,
whereas DC2 and DC5 cells showed the highest quotients
in this experiment. DCs matured with cocktails DC3 and
DC4 also secreted more IL-12p70 than IL-10 and were
superior to DC1 cells in this respect. Variations were noted
in the capacity of DCs derived from different donors to
produce these cytokines (Table 4). Nevertheless, DC2–
DC5 cells were always superior to DC1 cells with respect
to IL-12p70/IL-10 values.
Allostimulatory capacity of DCs
To evaluate DC function, we utilized mixed lymphocyte
reactions employing mDCs as stimulating cells with
autologous and allogeneic T cells. T cell proliferation
against third party cells and PHA plus IL-2 or IL-2 alone
served as positive controls, demonstrating that both autol-
ogous and allogeneic T cells had strong proliferative
potential (data not shown). Irradiated DCs alone did not
proliferate (Fig. 4A), verifying that the assay only detected
T cell responses. As expected, autologous T cells prolifer-
ated less well than allogeneic T cells following DC stimu-
lation (Fig. 4B versus 4C). Figure 4D summarizes
responses of three independent allogeneic responder T
cells versus autologous T cells with the various DCs of the
selected donor. As expected, all the different mDCs
induced strong alloresponses due to MHC disparity how-
ever responses were somewhat lower using DC2 cells.
Table 5 demonstrates that DCs matured in all five matura-
tion cocktails had substantial allostimulatory capacity in
three independent experiments.
Induction of IFNγ secretion by T cells following coculture 
with peptide-pulsed DCs
The capacity of the same DC populations to present pep-
tides was tested using a set of virus-specific peptides
derived from cytomegalovirus, Epstein-Barr virus, and
influenza virus (CEF peptides) (Fig. 5). Autologous lym-
phocytes of ELUTRA fraction 3 of the HLA-A*0201-posi-
tive DC donor were stimulated for 7 days with peptide-
pulsed DCs matured in the various cocktails. Activated
lymphocytes recovered from the cocultures with DC1,
DC3, DC4 and DC5 cells were then restimulated for 24 h
with autologous monocytes, which were cryopreserved
following elutriation on day 0 (Fig. 1), with or without
addition of CEF peptides. It was not possible to assess the
stimulating capacity of DC2 cells in this assay due to
insufficient cell recoveries. The capacity of the DC-acti-
vated lymphocytes to secrete IFNγ in response to peptide-
restimulation was assessed in a standard ELISPOT assay.
Increased responses were seen in the presence of CEF pep-
tides in all cases, demonstrating that DCs matured in our
cocktails could present peptides and reactivate memory T
cells with efficiencies comparable to DCs matured in DC1
(Jonuleit) cocktail. It should be noted here that this capac-
ity has been demonstrated elsewhere for DC2 cells
(matured in Kalinski cocktail) [20].
Expression of protein following RNA transfer into DCs by 
electroporation
RNA is an attractive alternative source to provide antigens
to DCs, whereby a whole protein is directly translated in
the cytosol and made available to DCs for peptide
processing and presentation, thereby bypassing the need
to know specific MHC-binding peptides. To test the capac-
ity of DCs to express protein after loading with in vitro
transcribed RNA, we analyzed EGFP expression by flow
cytometry after transfer of corresponding RNA. Mature
DCs were generated from cyropreserved monocytes
obtained by leukapheresis and elutriation according to
Table 4: Signal-3 assay of cytokine production by DCs matured in different cocktails
Parameter DC1 DC2 DC3 DC4 DC5
N * 75473
IL-12p70(pg/ml) m+ 2.6 432.7 346.4 181.4 466.2
std# 4.5 313.3 529.3 290.9 318.3
IL-10(pg/ml) m+ 25.3 153.0 61.5 52.9 157.3
std# 34.6 124.5 51.7 45.1 64.3
IL-12p70/IL-10(quotient) m+ 0 5.1 4.2 5.2 3.9
std# 0 7.2 6.6 7.4 3.8
* N = number of independent donors
+ m = mean
#std = standard deviationJournal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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Table 5: Stimulation of autologous and allogeneic PBLs using DCs matured in different cocktails
Parameter DC1 DC2 DC3 DC4 DC5
DCs only control (cpm) N* 3 3 2 3 2
m+ 636.3 639.5 659.7 518.5 607.7
std# 98.7 145.3 207.7 165.5 63.4
Autologous PBLs(cpm) N* 3 3 2 3 2
m+ 3704.9 3291.9 3498.4 5490.7 2864.1
std# 2602.9 2619.3 4611.8 6022.2 3012.1
Allogeneic PBLs(cpm) N* 7 7 5 7 5
m+ 37531.5 28635.2 38513.0 36918.9 37052.2
std# 4313.8 5661.2 7935.8 11058.8 5142.4
* N = number of independent donors
+ m = mean
# std = standard deviation
Analysis of allostimulatory capacity of different DCs in mixed  lymphocyte reactions Figure 4
Analysis of allostimulatory capacity of different DCs 
in mixed lymphocyte reactions. (A) Negative controls of 
proliferation of irradiated (40 Gy) DCs alone. (B) Prolifera-
tion of autologous T cells stimulated by DC1–DC5 popula-
tions. (C) Proliferation of one representative allogeneic T cell 
responder stimulated by DC1–DC5 cells. Note that the y-
axis is different for autologous and allogeneic T cell 
responses. (D) Summary of proliferation data of three inde-
pendent allogeneic T cell responders in comparison to autol-
ogous T cells stimulated by DC1–DC5 cells.
Response of autologous lymphocytes from an HLA-A*0201- positive donor responding to virus-peptide pulsed DCs Figure 5
Response of autologous lymphocytes from an HLA-
A*0201-positive donor responding to virus-peptide 
pulsed DCs. T cell responses were assessed in an IFNγ-
ELISPOT experiment using peripheral blood lymphocytes 
(PBLs: T cell enriched ELUTRA fraction 3 = 54.8% CD3 posi-
tive cells) that were first activated for 7 d with mature pep-
tide-pulsed DCs and then restimulated for 24 h with 
monocytes plus CEF peptides. For the ELISPOT analyses, 4 × 
103 autologous in vitro activated lymphocytes were stimulated 
with 2 × 103 monocytes together with the CEF peptide pool. 
The mean ± S.D. was calculated for triplicate wells. Note: 
Due to insufficient recoveries, lymphocytes activated by DC2 
cells were not included in the assay. Because of limitations in 
HLA-A2 subtyped donors available for leukapheresis, this 
experiment was only included once in the full DC evaluation 
protocol.Journal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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the time-line shown in Figure 1. Due to limitations in cell
numbers, DC3 cells were not included because cocktail
DC3 was identical to cocktail DC4, except for lower
amounts of IFNγ and PGE2 (Table 1). On day 6, the dif-
ferent maturation cocktails were added to the iDCs and on
day 7, RNA was introduced into the mDCs via electropo-
ration. In previous studies using DCs matured in DC1
(Jonuleit) cocktail, EGFP expression was found to peak
12–24 h following RNA transfection and expression was
stable for 48 h [28]. Therefore, percentages of EGFP-posi-
tive cells and mean fluorescence intensities (MFI) were
measured 24 and 48 h after electroporation. DC1 and
DC4 cells expressed EGFP whereas DC2 cells did not
express EGFP and DC5 cells expressed no (Fig.6) or only
very low levels of EGFP (data not shown). This same pat-
tern was seen at 48 h (data not shown). Poly (I:C), which
was a component of cocktails DC2 and DC5 was not
present in cocktails DC1 and DC4. DC2 (Kalinski) cock-
tail also contained IFNα, which was not included in any
other cocktail. Interestingly, we found elsewhere that DCs
matured with IFNα alone also failed to express EGFP pro-
tein following RNA transfer [21].
Discussion
DC-based immunotherapy has been proven to be safe
with minimal side-effects and has shown some clinical
efficacy in patients with metastatic melanoma [29-31].
Induction of effective immune responses is dependent
upon proper maturation of DCs [32]. Such DCs provide
three interactive functional signals within an immunolog-
ical synapse of appropriate duration [33-35]. Signal 1 pro-
vides the specificity for an immune response through DC
presentation of MHC-peptide complexes to responding T
cells. Secondly, mature DCs provide positive amplifica-
tion of signal 1 transduction via costimulation (signal 2)
through molecules such as CD80, CD86 and CD40.
Thirdly, DCs translate the environmental patterns under
which they matured into the quality of effector cell
responses by secreting various cytokines (signal 3) that
regulate, for example, T helper cell polarization. Thus, IL-
12p70 secretion leads to Th1 responses which, in turn,
support the induction of CTLs, macrophages or DTH reac-
tions via production of IL-2, IFNγ and TNF. Alternatively,
IL-10 or TGFβ support Th2 responses that impact on anti-
body production, mast cell degranulation and eosi-
nophilia via secretion of IL-4, IL-5, IL-10, IL-13 [36,37].
Optimal adaptation of monocyte-derived DCs generated
in vitro for cancer vaccines needs to take these aspects into
account in order to improve treatments for malignant dis-
eases.
We established a closed bag system of elutriation using
leukapheresis products to obtain monocytic progenitor
cells for DC generation. The method required some
finesse, particularly regarding the adaptation of the leuka-
pheresis collection mode to assure low erythrocyte con-
tamination. During more than 20 elutriation runs (data
not shown), we noted individual variations based on
granulocyte levels; if these were high in peripheral blood,
granulocytes were often retained in fraction 5 due to their
similar size characteristics with monocytes. Removal of
platelets in fraction 1 was highly advantageous and was
not achieved with other monocyte-enrichment methods,
such as Ficoll-gradient centrifugation or magnetic-bead
separation (data not shown). The elutriation process with
the ELUTRA system proved to be generally feasible for
monocyte isolation, as also described by other groups
[38], and is easily adapted to GMP guidelines.
We evaluated several maturation cocktails for clinical use
with monocyte-derived iDCs generated using GM-CSF
and IL-4. DCs generated from the same leukapheresis
products using either elutriation or Ficoll separation and
Expression of EGFP in DCs transfected with EGFP-encoding  in vitro transcribed RNA Figure 6
Expression of EGFP in DCs transfected with EGFP-
encoding in vitro transcribed RNA. Flow cytometry his-
togram overlays show EGFP expression following RNA 
transfer into mDCs on day 7 (filled curves) 24 h after elec-
troporation and corresponding untransfected DCs (empty 
curves) as negative controls. DCs were matured in the four 
cocktails indicated, RNA was introduced by electroporation, 
the DCs were returned to their corresponding media con-
taining maturation cocktails and harvested for flow cytome-
try 24 h later (day 8). Numbers indicate the percentages of 
EGFP-positive DCs and their mean fluorescence intensities. 
These data are representative of two independent experi-
ments with measurements at 24 and 48 h.Journal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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subsequent plastic adherence had identical phenotypes
24 h after maturation with DC1 (Jonuleit) cocktail (data
not shown). This revealed that monocyte-derived DCs
prepared by elutriation were of the same quality.
RPMI 1640 medium based on ultra-pure water suitable
for patient injection and very low endotoxin content was
used for DC cultures. Protein supplementation was made
with 1.5% specialized human male AB-serum, pooled
from at least 20 donors. Sera were combined only after
each single donor was tested extensively for infection
markers at the time of donation and 4 months later. Addi-
tionally, the serum pool was demonstrated to be negative
for IL-12p70 and IL-10 (data not shown). According to
standard guidelines for blood products, this serum pool
should be suitable for the regulatory authorities. In con-
trast to other approaches utilizing autologous plasma/
serum [31], we considered that tumor patient-derived
proteins could be problematic in some instances due to
the presence of individual inhibitory cytokines. Use of a
standardized serum pool of healthy donors mostly free of
inhibitory cytokines would eliminate another variable in
small clinical trials. A complete synthetic medium would
be desirable but several commercially available serum-
free alternatives were not satisfactory in our hands.
Further, we created new maturation cocktails and com-
pared them with DC1 (Jonuleit) cocktail [19] and the
recently described DC2 (Kalinski) cocktail [20]. We also
evaluated several synthetic TLR7/8 ligands such as Resiq-
uimod (R848), Imiquimod (R837), Loxoribine, or poly
U-rich single-stranded RNA. As reported by Napolitani
and co-workers [39], we found the imidazoquinilone-
derivate R848 to be superior (data not shown), despite
positive influences on DCs by Imiquimod[40] and
Loxoribine [41]reported also by others.
Based on these comparisons, we developed a new cocktail
based on TNF, IL-1β, IFNγ, PGE2 and R848. Because of a
dose-dependent IL-12-inhibitory potential, the concentra-
tion of PGE2 was lowered compared to DC1 (Jonuleit)
cocktail but was retained in order to support induction of
CCR7 expression and improve harvesting feasibility
through reduced plastic adherence of the matured DCs.
To further amplify IL-12-inducing potency, poly (I:C) was
added to cocktail DC5. All cocktails induced high levels of
CD83 expression on DCs cultured for 7 days. Costimula-
tory molecules were also high on all cells and CCR7 was
present on over 60% of cells. DCs matured with the DC2
(Kalinski) cocktail showed somewhat lower viabilities
due to their strong adherence and presence of elongated
dendritic veils that hindered harvesting. In contrast to
published results [20], this appeared as a disadvantage in
our system, which was most apparent with respect to func-
tional assays and DC cryopreservation. Stability of matu-
ration is another important characteristic for clinically
applied DCs because patients with malignant diseases
often have high serum levels of inhibitory cytokines (e.g.
IL-10, TGF-β or IL-6). These cytokines may reverse DCs to
an immature status, which could then tolerize a patient's
immune system towards the immunizing tumor antigens.
DCs matured with all cocktails showed stable CD83
expression for two days after removal of cytokines, sug-
gesting irreversible maturation had occurred during this
time period in all DC populations.
Legal requirements for extensive cleaning and disinfection
of a GMP clean room between the handling of cells of dif-
ferent patients led us to develop a mode of DC generation
that would yield high numbers of cells that could be cry-
opreserved in a single batch in order to avoid repetitive
cultures for individual patients. It also has been shown
that it is possible to freeze mature DCs even after antigen
loading [22]. DCs matured with all the different cocktails
could be cryopreserved and still retained full CD83
expression after thawing. However, some loss of viability
was noted, particularly with DC2 and DC5 cells matured
in media containing poly (I:C).
Improved understanding of DC biology has led to contin-
ually evolving ideas regarding optimal DC-based vaccines.
The mere replacement of iDCs with phenotypically
mDCs, expressing high levels of MHC and costimulatory
molecules alongside the CCR7 homing receptor, must
now be extended by considerations regarding the various
roles that DCs play based on their cytokine secretion pat-
terns [42]. This consideration is reflected here by the dif-
ferent ratios of IL-12p70/IL-10 in DC1 (Jonuleit) cocktail
versus DC2 (Kalinski) cocktail. Such variations would
have the consequence of yielding DC vaccines with differ-
ent polarizing capacities. On one hand, immune
responses primed by some DCs could lead to induction of
regulatory cells that could be useful for transplant toler-
ance or autoimmunity, whereas others could induce Th1-
polarized immune responses desirable for optimal anti-
tumor immunity or Th2-directed responses that are essen-
tial for antibody responses critical for some infectious dis-
eases. DC-based vaccines that are generated in vitro must
also have the capacity to secrete cytokines upon contact
with T cells in vivo. A first assessment of cytokine capacity
was made using supernatant medium from primary DCs.
However, the signal-3 assay was important to evaluate
induction of cytokine secretion in a setting mimicking a T
cell encounter, with subsequent DC signalling via CD40L,
in order to demonstrate that the DCs were not exhausted
with respect to cytokine production [35]. IL-12p70 secre-
tion by DCs is stimulus dependent and underlies a short
kinetic [43]. Results of the signal-3 assay revealed that
DCs matured in cocktails DC2 and DC5 showed the high-
est levels of IL-12p70 secretion and DC2–DC5 cells wereJournal of Translational Medicine 2007, 5:18 http://www.translational-medicine.com/content/5/1/18
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all superior to DC1 cells with respect to IL-12p70/IL-10
ratios.
When all characteristics were taken together, DCs matured
with our cocktails, particularly cocktails 3 and 4, com-
bined the best characteristics of DC1 (Jonuleit) cocktail
with respect to phenotype, maturation stability, function
and recovery after cryopreservation, combined with the
additional capacity to produce IL-12p70. These findings
correlate with recent observations that inflammatory
cytokines alone are not able to induce full DC maturation
[18], but rather that DCs also require signals through TLR
or other innate, non-TLR pattern recognition receptors,
representing nature's way of engaging pathogens through
pattern recognition. The presence of the synthetic TLR8
ligand R848 in our media correlated with DC2 (Kalinski)
cocktail with respect to an IL-12-inducing capacity due to
a TLR-induced autocrine type 1 interferon loop [44]. The
cytotoxic property of IFNα, present in DC2 cocktail, may
have contributed to poor DC viability. Viability may have
been further impacted by the presence of poly (I:C),
which signals through distinct pathways, including endo-
somal TLR3 but mainly via RNA-sensing helicase domain-
containing proteins within the cytosol [45,46]. Endo-
somal TLR7/8 signalling by R848[41,47] showed no neg-
ative impact on cell viability, at least not at the
concentration of 1 μg/ml used here. In contrast to Napoli-
tani et al. [39], we presume that synergistic stimulation
through poly (I:C) and R848, may lead to over-stimula-
tion of DCs with some induction of apoptosis, explaining
the lower viability of DCs matured in cocktail DC5.
Furthermore, we found that the addition of poly (I:C) to
the basic components of cocktail DC4, creating the DC5
cocktail, prevented DC5 cells from being able to express
protein after loading with exogenous RNA, presumably
through induction of mechanisms to protect cells from
foreign RNA [47]. This restriction of RNA expression was
similar to the behaviour of DCs matured in DC2 (Kalin-
ski) cocktail, which also contained poly (I:C). Thus, DCs
matured in medium containing poly (I:C) appear unsuit-
able for use in RNA-based vaccines, although both are
clearly suitable for use with peptides, as shown here for
cocktail DC5 and published previously for DC2 (Kalinski)
cocktail [20]. In contrast, DCs matured in cocktails DC3
and DC4 would be well suited for generating IL-12p70-
producing mDCs for cancer vaccine development using
either peptides or RNA as sources of tumor-associated
antigens.
Conclusion
Here we describe new maturation cocktails that can be
used to generate human monocyte-derived dendritic cells
with IL-12p70-secreting potential after CD40L stimula-
tion. These mDCs show good harvesting characteristics
and their generation can be easily adapted for compliance
with good manufacturing practice. Our preferred cocktail
is the DC4 cocktail, which combines the best characteris-
tics of the current "gold standard" DC1 (Jonuleit) cocktail
and the recently published alternative DC2 (Kalinski)
cocktail. DCs prepared with cocktail DC4 are suitable for
use with RNA, in addition to peptides, as a source of
tumor-associated antigens.
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